Who are Ketamine plus magnesium group's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Namenda, Felbatol, QUINIDINE, Methadone Hydrochloride, Nitrous Oxide 99 %, Ketamina-Propofol Combination.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ketamine-plus-magnesium-group.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Ketamine plus magnesium group — Competitive Intelligence Brief

Ketamine plus magnesium group (Ketamine plus magnesium group) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NMDA receptor antagonist combination. Area: Oncology.

phase 3 NMDA receptor antagonist combination NMDA receptor Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Ketamine plus magnesium group (Ketamine plus magnesium group) — National Cancer Institute, Egypt. Ketamine blocks NMDA receptors while magnesium enhances this antagonism and may provide neuroprotective and anti-inflammatory effects.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Ketamine plus magnesium group TARGET	Ketamine plus magnesium group	National Cancer Institute, Egypt	phase 3	NMDA receptor antagonist combination	NMDA receptor
Namenda	MEMANTINE	AbbVie	marketed	N-methyl-D-aspartate Receptor Antagonist	Glutamate NMDA receptor; GRIN1/GRIN2A	2003-01-01
Felbatol	FELBAMATE	Mylan Speciality Lp	marketed	Anti-epileptic Agent [EPC]	NMDA receptor-ionophore complex	1993-01-01
QUINIDINE	QUINIDINE		marketed		sigma-1 receptor, NMDA receptor, CYP2D6	1950-01-01
Methadone Hydrochloride	METHADONE	Specgx Llc	marketed	Opioid Agonist	mu-opioid receptors, NMDA receptor	1947-01-01
Nitrous Oxide 99 %	Nitrous Oxide 99 %	Unity Health Toronto	marketed	Inhalational anesthetic	NMDA receptor
Ketamina-Propofol Combination	Ketamina-Propofol Combination	Universidad de Cartagena	marketed	Anesthetic combination	NMDA receptor (ketamine); GABA-A receptor (propofol)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NMDA receptor antagonist combination class)

Ain Shams University · 1 drug in this class
National Cancer Institute, Egypt · 1 drug in this class
National Cheng-Kung University Hospital · 1 drug in this class
University of Chile · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ketamine plus magnesium group — Competitive Intelligence Brief. https://druglandscape.com/ci/ketamine-plus-magnesium-group. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab